Key result
Delivery of miR-21 efficiently protected against early impairment in cardiac diastolic dysfunction and relieved diabetes-induced cardiomyocyte hypertrophy by targeting gelsolin in db/db mice.
Why the study?
Does miR-21 overexpression improve cardiac diastolic dysfunction in models of diabetic cardiomyopathy?
Does miR-21 overexpression improve cardiac diastolic dysfunction in models of diabetic cardiomyopathy?
p-value: p=<0.05
miR-21 attenuates diabetic cardiomyopathy and diastolic dysfunction by targeting gelsolin, suggesting a potential miRNA-based therapeutic target.
No takes yet. Share an insight, caveat, or question.
miR-21 may protect diastolic function in diabetic cardiomyopathy models; extends preclinical data but leaves open human translation.
B et al. (2018) studied Diabetic cardiomyopathy (n=32). miR-21 overexpression (rAAV-tnt-miR-21) vs. rAAV-tnt-GFP (control) was evaluated on Cardiac diastolic dysfunction and cardiomyocyte hypertrophy (p=<0.05). Delivery of miR-21 efficiently protected against early impairment in cardiac diastolic dysfunction and relieved diabetes-induced cardiomyocyte hypertrophy by targeting gelsolin in db/db mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: